Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S23 pseudogene 2 (RPS23P2) is a processed pseudogene in the human genome that shares sequence similarity with the functional ribosomal protein S23 gene (RPS23). Pseudogenes are non-functional DNA sequences resulting from duplication or retrotransposition events; they generally do not encode proteins and are not considered therapeutic or pharmacological targets[1][2][5][11]. RPS23P2 does not have any known biological function, disease association, or relevance in drug development. The gene is assigned as a pseudogene by authoritative genome annotation projects and is not referenced as a target in therapeutic, diagnostic, or research contexts[1][2][8][11]. RPS23P2 is not a protein, receptor, enzyme, or other conventional drug target but rather a non-functional remnant of a gene, and therefore does not fit the usual criteria for molecular target databases or drug development[1][2][11][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S23 pseudogene 2 (RPS23P2).